The founders of NormOxys are working to commercialize molecules similar to those that give migratory birds the fortitude to fly thousands of miles. When the compound inositol pentaphosphate binds to the protein hemoglobin, its presence helps release up to three of the four oxygen molecules that hemoglobin picks up in the lungs and carries out to the body. NormOxys is betting that its lead candidate can help elevate oxygen levels in human tissues that lack it, and so become a treatment for a range of disorders, from heart failure to diabetic retinopathy, traumatic blood loss, and even cancer.
16 Laurel Avenue
Suite 150
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.
South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.
